12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

LIPOchip regulatory update

The U.K.'s NICE issued final guidance recommending against the use of the genetic tests Elucigene FH20 from Gen-Probe Inc. (NASDAQ:GPRO, San Diego, Calif.) and LIPOchip from Progenika Biopharma to confirm a clinical diagnosis of familial hypercholesterolemia ( FH) or for the screening...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >